How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer.

---

This podcast is supported by:

Ferring Pharmaceuticals

---

SYNPOSIS

The doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice.

---

TIMESTAMPS

00:00 - Introduction
04:05 - Surveillance and Follow-Up Strategies
10:10 - Biomarkers in Bladder Cancer
18:02 - Blue Light Cystoscopy and Patient Comfort
30:56 - Risk Assessment and Counseling
42:56 - Future of Bladder Cancer Diagnostics
47:00 - Concluding Thoughts

---

RESOURCES

CxBladder Study
https://www.sciencedirect.com/science/article/pii/S1078143923000091

Lars Dyrsakjot Study on Tumor Markers
https://pmc.ncbi.nlm.nih.gov/articles/PMC7690647/

The Bridge Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/